LAURUSLABS

Key Updates

Laurus Labs — Key Updates 1. Strong Revenue & Profit Rebound Laurus Labs has posted strong revenue growth in the last few quarters. Profit has jumped sharply, driven by improving margins and a strong recovery in core businesses. EBITDA margins have expanded meaningfully, showing operating leverage. 2. CDMO Business is the Big Growth Driver The Contract Development & Manufacturing (CDMO) division is growing rapidly and contributing a larger share of revenue. Small-molecule CDMO is doing especially well, and the company is positioning itself as a major global player. Management expects CDMO to deliver high margins and become the largest part of the business in the coming years. 3. Generics Business Stable to Improving API volumes are stabilizing after a weak period. The formulations segment is also showing an upward trend. Higher-margin products are improving the overall profitability mix. 4. Heavy CapEx but Positive Long-Term Story Laurus is making major investments in new manufacturing capacity, research infrastructure, and advanced chemistry capabilities. CapEx is high now, but the payoff is expected over the next 2–4 years as new facilities commercialize. The company is also developing a large pharma manufacturing zone in Andhra Pradesh, which can give scale and cost advantage.